{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARV+regimen&page=2", "query": { "intervention": "ARV regimen", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARV+regimen&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T02:59:33.689Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01923311", "title": "Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "EVG", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 31, "start_date": "2013-08-26", "completion_date": "2017-11-03", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 3, "location_summary": "Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01923311" }, { "nct_id": "NCT00703586", "title": "Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2007-09", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2012-10-23", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00703586" }, { "nct_id": "NCT02859558", "title": "Early ART to Limit Infection and Establishment of Reservoir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2017-01-24", "completion_date": "2025-04-16", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 23, "location_summary": "Birmingham, Alabama • San Diego, California • Torrance, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859558" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT00624195", "title": "Clinical Trial of CNS-targeted HAART (CIT2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "FDA Approved Antiretroviral Therapy (see list below)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2007-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 5, "location_summary": "San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624195" }, { "nct_id": "NCT01967940", "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "Current failing ARV regimen", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-10-25", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 5, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967940" }, { "nct_id": "NCT01363011", "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2011-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363011" }, { "nct_id": "NCT05502341", "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" }, { "name": "BIC/LEN FDC", "type": "DRUG" }, { "name": "Stable Baseline Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 689, "start_date": "2022-08-16", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 40, "location_summary": "Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05502341" }, { "nct_id": "NCT00067587", "title": "Metabolic Abnormalities in HIV Infected and Uninfected Young Women", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections", "Hypercholesterolemia", "Glucose Intolerance" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "24 Years", "sex": "FEMALE", "summary": "12 Years to 24 Years · Female only" }, "enrollment_count": 300, "start_date": "2003-07", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 11, "location_summary": "Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067587" }, { "nct_id": "NCT02469246", "title": "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "ABC/3TC Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "3rd ARV agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-06-29", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-09-27T02:59:33.689Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469246" } ] }